GLP-1 drugs show potential in treating alcohol use and asthma

Research into GLP-1 receptor agonists, such as semaglutide, suggests these medications may offer therapeutic benefits beyond treating type 2 diabetes and obesity.

A study presented at the European Respiratory Society Congress indicates that patients using these drugs may experience up to a 40% reduction in asthma attacks. Researchers from Imperial College London analyzed real-world electronic health records in the United Kingdom to investigate whether individuals with asthma or COPD who were prescribed GLP-1 agonists experienced fewer acute respiratory crises.

Additionally, clinical observations have highlighted a potential link between GLP-1 treatment and reduced alcohol consumption. A randomized clinical trial published in The Lancet involving 108 patients with moderate to severe alcohol use disorder and obesity showed that those receiving subcutaneous semaglutide experienced a significant reduction in total alcohol intake compared to a placebo group.

While these findings are considered encouraging, medical experts emphasize that they should not currently alter standard therapeutic guidelines. Further clinical trials are required to confirm these respiratory and behavioral benefits.